PuSH - Publikationsserver des Helmholtz Zentrums München

Schnell, O.* ; Barnard-Kelly, K.* ; Battelino, T.* ; Ceriello, A.* ; Larsson, H.E.* ; Fernández-Fernández, B.* ; Forst, T.* ; Frias, J.P.* ; Gavin, J.R.* ; Giorgino, F.* ; Groop, P.H.* ; Heerspink, H.J.L.* ; Herzig, S. ; Hummel, M.* ; Huntley, G.* ; Ibrahim, M.* ; Itzhak, B.* ; Jacob, S.* ; Ji, L.* ; Kosiborod, M.* ; Lalic, N.* ; Macieira, S.* ; Malik, R.A.* ; Mankovsky, B.* ; Marx, N.* ; Mathieu, C.* ; Müller, T.D. ; Ray, K.K.* ; Rodbard, H.W.* ; Rossing, P.* ; Rydén, L.* ; Schumm-Draeger, P.M.* ; Schwarz, P.* ; Škrha, J.* ; Snoek, F.* ; Tacke, F.* ; Taylor, B.* ; Jeppesen, B.T.* ; Tesfaye, S.* ; Topsever, P.* ; Vilsbøll, T.* ; Yu, X.* ; Standl, E.*

CVOT Summit Report 2023: New cardiovascular, kidney, and metabolic outcomes.

Cardiovasc. Diabetol. 23:104 (2024)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5-6, 2024 ( http://www.cvot.org ).
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Letter to the Editor
Korrespondenzautor
Schlagwörter Cgm ; Cardiovascular Disease ; Chronic Kidney Disease ; Diabetes ; Finerenone ; Glp-1 Ra ; Guidelines ; Heart Failure ; Masld ; Nafld ; Obesity ; Sglt2 Inhibitor ; Teplizumab; Double-blind; Diabetic Polyneuropathy; Receptor Agonist; Glycemic Control; Type-2; Efficacy; Placebo; Safety; Multicenter; Disease
ISSN (print) / ISBN 1475-2840
e-ISSN 1475-2840
Zeitschrift Cardiovascular Diabetology
Quellenangaben Band: 23, Heft: 1, Seiten: , Artikelnummer: 104 Supplement: ,
Verlag BioMed Central
Verlagsort Campus, 4 Crinan St, London N1 9xw, England
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Cancer (IDC)
Institute of Diabetes and Obesity (IDO)